Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 33.78% on an annualized basis producing an average annual return of 46.67%. Currently, Moderna has a market capitalization of $43.33 billion.
Buying $1000 In MRNA: If an ...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 33.78% on an annualized basis producing an average annual return of 46.67%. Currently, Moderna has a market capitalization of $43.33 billion.
Buying $1000 In MRNA: If an ...
Market Wire News is a media platform, the information on this page was provided by Benzinga via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...